Cyclo-oxygenases (COXs) catalyse the synthesis of PGH 2 (prostaglandin H 2 ), which serves as the common substrate for the production of PGE 2 , PGD 2 , PGF 2α , prostacyclin (or PGI 2 ) and TXs (thromboxanes). While COX-1 is the major isoform responsible for prostanoid synthesis in healthy tissues, little information is available on the contribution of constitutive COX-2 to the various prostanoid synthetic pathways under non-inflammatory conditions. To evaluate further the role of COX-2 in prostanoid biosynthesis, rats were acutely treated with the selective COX-1 inhibitor SC-560
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) exert their effects by inhibiting the enzyme cyclo-oxygenase (COX) [1] , which exists as two major isoforms, COX-1 and COX-2. Most, if not all, of the efficacy of NSAIDs as anti-inflammatory agents is due to inhibition of COX-2 [2] . The COX-2 enzyme is generally undetectable or present at low levels in resting state but is induced by various stimuli like bacterial endotoxins, inflammatory cytokines and growth factors, as opposed to COX-1, which is constitutively expressed in most of the tissues [3] . These enzymes catalyse the first step in the conversion of arachidonic acid into prostanoids, including PGs (prostaglandins) (PGE 2 , PGI 2 , PGD 2 and PGF 2α ) and TXs (thromboxanes) (TXA 2 ) [4] . Prostanoids are a family of paracrine and autocrine mediators that possess multiple biological functions [5] . For example, PGE 2 is implicated in the maintenance of gastrointestinal integrity, in fever generation, in allodynia and hyperpalgaesia, as well as in inflammation [6] .
Although it is mainly induced by pro-inflammatory stimuli, COX-2 has been found to be constitutively expressed in some tissues including brain [7] , kidney [8] , lung [9] and reproductive organs [10] . Particularly, in the central nervous system, COX-2 has been detected predominantly in cortex, hypothalamus, hippocampus, amygdala and spinal cord [7, 11] . The role of the constitutive COX-2 in the brain has not been defined, but it is speculated to play a role in nerve transmission, as COX-2 expression is upregulated by nerve activity [12, 13] . Also, COX-2 is induced in the brain after inflammatory stimuli and it is implicated in fever generation and hyperalgaesia [12] . As for the kidney, COX-2 protein expression has been detected in the macula densa and associated cortical thick ascending limb of Henle's loop, in medullary interstitial cells, and to a lower level in the inner medullary collecting duct [8, 14, 15] . COX-2 is thought to play a role in regulation of renal perfusion, since high-salt diets induce COX-2 expression in renal medulla [14] , as well as in salt and water excretion, since low-salt diet or loop diuretics increase COX-2 cortical expression in the macula densa [16, 17] . Moreover, selective COX-2 inhibitors and NSAIDs tend to cause acute salt and water retention in healthy subjects [18] .
COXs act in concert with terminal synthases for the production of the various prostanoids. For example, mPGES-1 (microsomal PGE 2 synthase-1) has been shown to preferentially couple with COX-2, as compared with COX-1, in stably transfected cells [19] . Up-regulation of COX-2 by interleukin-1β in human umbilical vein endothelial cells leads to selective increases in PGE 2 and 6-oxo-PGF 1α production as compared with TXB 2 [20] . These apparent couplings of terminal synthases with COXs could be explained by physical coupling, different kinetic properties of terminal synthases or simply co-ordinate up-regulation of the COX and a specific terminal synthase. In animal models of carrageenaninduced paw oedema and lipopolysaccharide-induced pyresis, the co-induction of mPGES-1 and COX-2 is responsible for the observed elevated PGE 2 production in the central nervous system [21, 22] .
Abbreviations used: COX, cyclo-oxygenase; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2-(5H)-furanone; ED 50 , effective dose; LC-MS, liquid chromatography MS; MF tricyclic, 3-(3,4-difluorophenyl)-4-(4-(methylsulphonyl)phenyl)-2-(5H)-furanone; NSAID, non-steroidal anti-inflammatory drug; PG, prostaglandin; mPGES-1, microsomal PGE 2 synthase-1; SC-560, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole; TX, thromboxane. 1 To whom correspondence should be addressed (email denis riendeau@merck.com).
As indicated above, data from in vitro studies raise the possibility that COX-2 could preferably couple with terminal synthases for the production of PGI 2 or PGE 2 . In addition, COX-2 slightly differs from COX-1 in its sensitivity to activation by exogenous arachidonic acid [23] , in its response to peroxide tone [24] , and in its coupling with different phospholipases [25] . It is thus difficult to estimate relative activities of COX-1 and COX-2 from in vitro or ex vivo assays since the conditions of activation of both isoforms might not reflect the in vivo situation. The aim of the present study was to determine the contribution of COX-2 to the synthesis of prostanoids under conditions where the activity of COX-2 is dependent on physiological conditions for its supply of the arachidonic acid substrate. Our results demonstrate that constitutively expressed COX-2 in rat kidney and forebrain contributes significantly to the production of prostanoids for each of the PG, prostacyclin and TX pathways.
EXPERIMENTAL

Materials
The PG standards (6-oxo-PGF 1α , PGE 2 , PGD 2 , PGF 2α and TXB 2 ) used for LC (liquid chromatography)-MS quantification were purchased as solids from Cayman Chemicals (Ann Arbor, MI, U.S.A.) and were reweighed using a microbalance. Corresponding deuterated PGs and indomethacin were also purchased from Cayman Chemicals. The selective COX inhibitors MF tricyclic [3-(3,4- [28] were synthesized at Merck Frosst. Complete ® Protease Inhibitor tablets were purchased from Roche Diagnostics (Mannheim, Germany).
Animal procedures
All animal procedures were approved by the Animal Care Committee at the Merck Frosst Centre for therapeutic research (Kirkland, QC, Canada) and the guidelines established by the Canadian Council on Animal Care were followed. Male Sprague-Dawley rats (Charles River, St. Constant, QC, Canada) weighing 225-275 g were deprived of food but had free access to water for 16 h before administration of vehicle or inhibitors. Compounds were administered orally in a 0.5 % methylcellulose vehicle (10 ml/kg) for a period of 4 h. The inhibitor doses were selected in order to obtain potent inhibition of COX-1 with SC-560 (10 mg/kg) [27] or COX-2 with MF tricyclic (5 mg/kg) and DFU (10 mg/kg) [28] but also at an appropriate dose to ensure selectivity towards the other COX isoforms.
Preparation of tissues extracts
Animals were killed by pentobarbital injection (120 mg/kg, intraperitoneal) and tissues were collected as fast as possible, rinsed in PBS buffer containing 10 µM indomethacin and frozen in liquid nitrogen. Samples were kept at − 80
• C until analysis. Frozen tissues were pulverized in liquid nitrogen using a mortar and pestle until a fine powder was obtained. This powder was then homogenized in 7-10 vol. of ice-cold PBS (pH 7.4; supplemented with 2 mM dithiothreitol, 10 µM indomethacin and 1 × Complete ® Protease Inhibitor mixture) using a tissue tearer (Polytron PRO 200). The homogenates were subsequently sonicated on ice for 10-30 s (Cole-Parmer ultrasonic homogenizer, 50 % output) before being subjected to centrifugation for 10 min at 1000 g (4
• C). Supernatants were collected for LC-MS analysis, quantification of MF tricyclic concentration by HPLC, as well as protein quantification by a modified Bradford method (BioRad protein assay).
Quantification of prostanoid content in tissue homogenates by LC-MS
6-Oxo-PGF 1α (stable breakdown product of PGI 2 ), PGE 2 , PGD 2 , PGF 2α and TXB 2 (stable breakdown product of TXA 2 ) were detected in each sample by LC-MS. Sample aliquots (100 µl) were protein-precipitated by the addition of 150 µl of acetonitrile containing 2 ng/ml deuterated prostanoids that served as internal standards for quantification (d 4 -PGE 2 was used as internal standard for both PGE 2 and PGD 2 ). Samples were vortex-mixed and centrifuged at 1200 g for 10 min (4 • C) and the supernatants were transferred to a new 96-well plate. Samples (50 µl) were analysed by LC-MS. Details of the procedure as well as optimized parent mass and fragment mass sensitivity for each PG have been reported previously [21] . For the whole kidney samples in the DFU experiment, prostanoids were concentrated by solid-phase extraction before LC-MS in order to increase the detection limit. Briefly, 0.9 ml aliquots of whole kidney homogenates were protein-precipitated with 1.5 ml of acetonitrile containing deuterated internal standards. Samples were vortex-mixed, centrifuged at 1200 g (4
• C) for 10 min and supernatants (2 ml) were added to 4 vol. of water. The pH was then adjusted to 3-3.5 with dilute HCl and samples were applied on SEP-PAK C 18 cartridges (Waters, Milford, MA, U.S.A.) that had been prerinsed with methanol and water. Cartridges were then washed with hexane and prostanoids were eluted with ethyl acetate. The eluate was evaporated under N 2 and resuspended in 150 µl of acetonitrile/water (60:40, v/v) before prostanoid quantification by LC-MS.
Measurement of plasma and tissue levels of MF tricyclic
Aliquots of plasma or tissue extracts were protein-precipitated with 1 vol. of acetonitrile, vortex-mixed and centrifuged at 9000 g (4
• C) for 20 min. Supernatants were recovered and injected (100 µl) on to a 4.6 mm × 150 mm Zorbax RX-C 18 column (Agilent Technologies, Stockport, Cheshire, U.K.) using an Agilent 1100 HPLC system with UV detection at 275 nm. MF tricyclic was eluted at 1 ml/min using a linear gradient from 30 to 50 % acetonitrile versus 20 mM ammonium acetate/methanol (90:10, v/v) for 15 min. Quantification was achieved by comparison with a standard curve prepared with vehicle-treated samples to which were added known amounts of MF tricyclic.
Statistical analysis
The data were log-scaled so that underlying assumptions of equal variance and normality were better satisfied and standard oneway ANOVA was performed to compare the different treatment groups. Fisher's LSD (least significant difference) method was used as post-hoc analysis, and results were considered statistically significant at the P < 0.05 level. All data were back-transformed to original scale and are expressed as geometric means + − S.E.M., which was determined by analysis of the variance of all treatment groups.
RESULTS
Prostanoid levels in brain and kidney are selectively affected by COX-2 inhibitors
In order to evaluate the relative importance of each COX isoform on the basal generation of prostanoids, Sprague-Dawley rats were administered SC-560 (selective COX-1 inhibitor), MF tricyclic Animals were administered vehicle (0.5 % methylcellulose), SC-560 (10 mg/kg) or MF tricyclic (5 mg/kg) for 4 h and levels of total prostanoids (6-oxo-PGF 1α + PGE 2 + PGD 2 + PGF 2α + TXB 2 ) were determined for the indicated tissues. Error bars represent S.E.M. for n = 8-10 animals, and significantly different levels compared with matching vehicles are depicted above the corresponding bars as follows: *P < 0.05, **P < 0.001.
(selective COX-2 inhibitor) or vehicle for 4 h. The different tissues were then collected and the major prostanoids were quantified by LC-MS. Table 1 summarizes the data for the total amount of prostanoids measured in each tissue of vehicle-treated animals. Vena cava and lung tissues contained the highest level of total prostanoid content, while liver and kidney showed the lowest amounts. Furthermore, analysis of prostanoid profiles revealed differences among tissues. 6-Oxo-PGF 1α was the main prostanoid found in lung, lymph nodes, bladder and aorta. In the ileum, PGD 2 and 6-oxo-PGF 1α were the major products; the kidney contained predominantly PGF 2α and, in the forebrain and liver, the main PGs detected were PGF 2α and PGD 2 . As for vena cava, the prostanoids were almost evenly distributed among 6-oxo-PGF 1α , PGD 2 and TXB 2 . Figure 1 shows that treatment of the animals with the selective COX-1 inhibitor SC-560 (10 mg/kg) resulted in a significant decrease in total prostanoid levels in ileum, lymph nodes, bladder, aorta and kidney (60-75 % inhibition) and a more moderate inhibition in the lung (36 %). On the other hand, selective COX-2 inhibition with MF tricyclic (5 mg/kg) did not significantly affect total prostanoid content in any of these tissues with the exception of kidney where a 49 % inhibition was observed (Figure 1) . In this experiment, MF tricyclic was administered at a dose 2-5-fold higher than the ED 50 (effective dose) for anti-inflammatory effects 
Figure 2 Effect of selective COX-2 inhibition on total prostanoid content of rat kidney and forebrain
Vehicle (0.5 % methylcellulose) or DFU (10 mg/kg) was administered to rats for 4 h and total prostanoid levels were determined (6-oxo-PGF 1α + PGE 2 + PGD 2 + PGF 2α + TXB 2 ) by LC-MS. Error bars represent S.E.M. for n = 5-10 animals, and statistical significance is indicated above the corresponding bars as follows: *P < 0.05.
in COX-2-dependent models (ED 50 of 1 mg/kg in the rat model of adjuvant-induced arthritis and 2.8 mg/kg in the carrageenan-paw oedema assay; C.-C. Chan, personal communication). In addition, the plasma concentration of MF tricyclic (3.1 µM) was in the range of efficacious doses [26] and was sufficient to inhibit COX-2 (IC 50 = 0.5 µM), but lower than that causing inhibition of COX-1 (IC 50 15 µM) as determined by human whole blood assays in vitro [29] or using a cell assay with CHO (Chinesehamster ovary) cells transfected with rat COX-1 (IC 50 > 50 µM; results not shown). Furthermore, tissue concentrations of MF tricyclic were also measured (Table 2) , which indicate that MF tricyclic has a very good distribution in all tissues examined. In order to independently confirm the effect of COX-2 inhibition on renal prostanoids, another selective COX-2 inhibitor (DFU) was used (SC-560 was not repeated in this experiment). DFU has been shown to be efficacious as a COX-2 inhibitor in various models of inflammation in the rat at 1 mg/kg and to possess a very high degree of selectivity for COX-2 inhibition [28] . Administration of DFU (10 mg/kg) resulted in a significant 37 % inhibition (P < 0.05) of total renal prostanoids, confirming the effect observed with MF tricyclic (Figure 2) . In this experiment, the forebrain was also collected for analysis. A significant 35 % inhibition (P < 0.05) of prostanoid content in the forebrain was observed following DFU treatment (Figure 2) .
In the present experiments, the doses of SC-560 and MF tricyclic were carefully chosen to achieve efficient inhibition of each COX isoform while maintaining selectivity. To evaluate further the extent of COX inhibition caused by these inhibitors, an * Fold induction of cortex + medulla over whole kidney homogenates. The value for (cortex + medulla) is obtained by normalizing the detected prostanoid concentrations for mass (cortex × percentage mass of total kidney) + (medulla × percentage mass of total kidney).
† Statistically different (P < 0.05) from corresponding values of whole kidney level.
additional experiment was performed to compare the effect of the combined administration of SC-560 and MF tricyclic with that of the non-selective indomethacin (5 mg/kg). Total prostanoid content was measured 4 h post-administration and found to be strongly inhibited by the combination of inhibitors in the aorta, brain and kidney (Table 3 ). The extent of inhibition (73-83 %) with the combination was similar to that of indomethacin for the aorta and brain, and slightly lower than indomethacin for the kidney (71 versus 86 %). In the lung, the combination was ineffective whereas indomethacin caused inhibition comparable with that measured in the other tissues (77 %). These data indicate that efficient inhibition of total COX activity can be achieved in aorta, brain and kidney tissues, but not in the lung where SC-560 and MF tricyclic, administered alone or in combination, have slight or no effects on tissue prostanoid content.
Tissue processing can stimulate ex vivo prostanoid production
In all studies on the measurement of prostanoid levels, the tissues were flash-frozen in the presence of indomethacin to minimize the possibility of prostanoid production after tissue collection. Tissue dissection and preparation of subfractions were found to result in stimulation of prostanoid release and did not permit to enrich for fractions that might have been more sensitive to COX-2 inhibition. For example, dissection of one of the kidneys from a vehicle-treated group into cortex and medulla revealed that the total prostanoid content in each of the dissected tissues was higher than that observed in the whole kidney (Table 4 ). Rats were treated for 4 h with vehicle (0.5 % methylocellulose), the selective COX-1 inhibitor SC-560 (10 mg/kg) or the selective COX-2 inhibitor MF tricyclic (5 mg/kg). Kidneys were collected and analysed for prostanoid content. Error bars represent S.E.M. for n = 10 animals, and statistically significant differences from matching vehicles are indicated above the corresponding bars as follows: *P < 0.05, **P < 0.001.
The observed increase, once normalized for mass, corresponded to a 6.5-fold induction of total prostanoid content in dissected cortex and medulla compared with whole kidney homogenates. Interestingly, the observed increase was larger for PGE 2 and 6-oxo-PGF 1α as compared with the other prostanoids. Presumably, activation of phospholipases following tissue damage can stimulate arachidonic acid release and COX activity, leading to an increased prostanoid production in fractionated kidney extracts.
Profile of prostanoid content in kidney and brain following selective COX inhibition
To evaluate the individual importance of COX-1 and COX-2 in the different prostanoid pathways, the effect of selective COX inhibitors on the prostanoid profile was examined. Interestingly, in the kidney, a significant decrease in all individual prostanoids was observed following administration of either SC-560 or MF tricyclic ( Figure 3 ). The percentage inhibition caused by SC-560 was 81 % for 6-oxo-PGF 1α , 61% for PGE 2 , 41% for PGD 2 , 64 % for PGF 2α and 68 % for TXB 2 . The inhibition caused by MF tricyclic was 54 % for 6-oxo-PGF 1α , 28 % for PGE 2 , 49 % for PGD 2 , 53 % for PGF 2α and 47 % for TXB 2 . Statistical significance was obtained for every prostanoid, except PGE 2 . However, in two other independent experiments, PGE 2 levels were significantly inhibited in the kidney following COX-2 inhibition (60 % with MF tricyclic, P < 0.001 and 44 % with DFU, P < 0.05; results not shown).
In the forebrain, selective COX-2 inhibition caused a significant decrease in all individual prostanoid levels, with the exception of PGD 2 (Figure 4 ). The inhibition caused by DFU was 41 % for 6-oxo-PGF 1α , 29% for PGE 2 , 17% for PGD 2 (not significant) and 59 % for PGF 2α . In summary, these data demonstrate that the inhibition of constitutively expressed COX-2 results in decreased levels of several major prostanoids of kidney and brain, including those of the major PGI 2 and PGE 2 pathways.
DISCUSSION
The present study focused on the role of constitutive COX-2 in the production of PGs and TX. By analysing the effects of selective COX-2 inhibitors on tissue prostanoid levels in rats, we show that constitutive COX-2 is catalytically active in kidney and forebrain Rats were treated for 4 h with vehicle (0.5 % methylcellulose) or the selective COX-2 inhibitor DFU (10 mg/kg). The forebrain was collected and analysed for prostanoid content. Error bars represent S.E.M. for n = 10 animals, and statistically significant differences from matching vehicles are indicated above the corresponding bars as follows: *P < 0.05, **P < 0.001. nd, not detected.
under non-inflammatory conditions. No significant contribution of COX-2 to prostanoid synthesis in any other tissue examined was detected using whole tissue extracts. Moreover, the results of the present study suggest that COX-2 can be limiting for the constitutive synthesis of each of the PGE 2 , PGI 2 and TX pathways in kidney and forebrain.
Production of prostanoids during processing of tissues
By measuring the tissue levels rather than the ex vivo or in vitro production of prostanoids, our objective was to obtain a more accurate estimation of COX-2-mediated prostanoid production under conditions where enzyme activity is dependent on endogenous release of the arachidonic acid substrate. To minimize post-harvesting production of prostanoids, especially in tissues where COX-2 is expressed at low levels compared with COX-1, tissues were harvested rapidly, flash-frozen, ground using liquid nitrogen and homogenized in a buffer containing indomethacin. The results obtained from the dissection of the kidney indicate that levels of prostanoids can be induced easily by tissue manipulation and that special care needs to be taken in order to measure levels that accurately reflect the basal levels in vivo. Although it is virtually impossible to ascertain that the measured levels correspond to the in vivo levels and that the extent of inhibition might be underestimated, the contribution of constitutive COX-2 to the production of prostanoids in kidney and brain, as well as the particular sensitivity of these tissues to selective COX-2 inhibition, was demonstrated in the present experiments.
Relative contribution of COX-1 and COX-2 to prostanoid synthesis
The results obtained with the selective inhibitor SC-560 confirmed the predominant role of COX-1 in the synthesis of prostanoids in most tissues [12] . Inhibition of COX-2 with the selective inhibitors did not affect the prostanoid content in any of the selected tissues, with the exception of brain and kidney.
The reduction of renal prostanoid levels by selective COX-2 inhibition was confirmed with two different inhibitors (DFU and MF tricyclic). These results are in line with previous experiments in which ex vivo brain PGF 2α production along with kidney PGE 2 and 6-oxo-PGF 1α production was found to be slightly inhibited by the selective COX-2 inhibitor NS-398 administered at 3 and 9 mg/kg (28 % inhibition of brain PGF 2α , P < 0.05, and a nonsignificant 20 % inhibition for kidney PGE 2 and 6-oxo-PGF 1α ) [30] . However, the results on the inhibition of renal COX-2 are in contrast with those observed in kidney extracts using added arachidonic acid for which PGE 2 production is COX-1-dependent [31] . The lack of inhibition of prostanoid synthesis following selective COX-2 inhibition in ex vivo or in vitro assays where exogenous arachidonic acid is added, as opposed to the results presented here, suggests that the availability of arachidonic acid might be more limiting for the activity of COX-1 as compared with COX-2 in the kidney under basal conditions.
The lung constitutively expresses both COX-1 and COX-2; however, this tissue was found to be rather insensitive to inhibition by SC-560 and MF tricyclic (a low level of inhibition was detected with SC-560 and was not confirmed in the combination experiment). A complication for analysis of the lung tissue is that euthanasia (by barbiturates and other methods) has been shown to affect the pulmonary vasculature [32] , which could result in a stimulation of prostacyclin production (6-oxo-PGF 1α was the major product detected in lung extracts), therefore masking the inhibitory effects of the selective inhibitors. In this case, the very slow off-rate of indomethacin from both forms of COXs [33] might have contributed to the maintenance of enzyme inhibition, which could explain the higher level of inhibition compared with that of SC-560, which is more rapidly reversible [34] . It is also possible that the inhibitors used do not reach the site of active COX; more work will be required to define the contribution of COX-1 and COX-2 to prostanoid synthesis in the lung.
Kidney and brain prostanoid profiles
In the kidney and forebrain, COX-2 inhibition caused a decrease in the concentration of all the individual prostanoids measured, except brain PGD 2 . This suggests that COX-2 can be limiting for the synthesis of a fraction of the prostanoids in these tissues. Of the two major PGs of the forebrain, PGF 2α was inhibited, while PGD 2 was not significantly affected by selective COX-2 inhibition. These results can be interpreted in many ways, one of which could be preferential coupling of COX-1 with PGD 2 synthase in this tissue under normal conditions. Alternatively, PGD 2 might have a slower turnover than the other prostanoids in the brain and might not have been produced to a significant level during the 4 h treatment period. Conversely, in the kidney, the individual PGs were all inhibited to a similar degree (∼ 50 %); hence the data do not provide any evidence of preferential coupling of COX-2 with a specific terminal synthase pathway at the whole tissue level, although coupling in subcompartments of the kidney [35] cannot be excluded.
It is well known that COX-2 inhibitors and NSAIDs can cause fluid retention and increase blood pressure [36] . The importance of COX-2-derived prostanoids in the regulation of renal physiology is well established [37] , but the exact PGs implicated in these phenomena have not been clearly identified. Results obtained from mice lacking the prostacyclin receptor suggest that prostacyclin is the key player for stimulation of renin release in response to renal artery stenosis [38] . However, PGE 2 has also been proposed to be important for the stimulation of renin release, as the rate of renin secretion was stimulated by PGE 2 in perfused kidneys of mice [39] . This stimulation was less important in kidneys isolated from mice lacking either of the PGE 2 receptors EP 2 and EP 4 [39] . These reports suggest that prostanoids, especially PGI 2 and PGE 2 , can both play a role in regulating renal physiology. Moreover, since COX-2 inhibitors affect both of these prostanoid pathways in the kidney, selective inhibitors of terminal synthases, such as mPGES-1 [40] , have the potential to differ from COX-2 inhibitors or NSAIDs with regard to renal side effects.
